Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

100%(2 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_3

67%

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 3Large-scale testing

2(66.7%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 32 (66.7%)

N/A1 (33.3%)

Trials by Status

completed267%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

completednot_applicable

Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention

NCT04522245

completedphase_3

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

NCT00669331

terminatedphase_3

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

NCT00359632

Clinical Trials (3)

Showing 3 of 3 trials

NCT04522245Not Applicable

Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention

Completed

NCT00669331Phase 3

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

Completed

NCT00359632Phase 3

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

Terminated

All 3 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 3